Nl swathi

@manipal.edu

PhD Research Scholar, Department of Nursing
Manipal Academy of Higher Education

Nl swathi


                           Download Compact PDF  
https://researchid.co/nl.swathi
I am a Pharm D graduate (March 2025) from Jawaharlal Nehru Technological University, India, and an currently PhD scholar in Public Health at Manipal Academy of Higher Education. My research spans diabetes management, cardio-metabolic health, precision medicine, and computational drug discovery, with a focus on integrating clinical research and public health strategies to improve patient outcomes.

I have held roles as a Research Mentor and Article Editor, Clinical Research Coordinator and Public Health Intern (ICMR-NIE), contributing to projects in diabetes epidemiology, drug development, and health systems research. I have authored and co-authored peer-reviewed articles and book chapters published in Current Problems in Cardiology, Primary Care Diabetes, and the Journal of Basic and Clinical Physiology and Pharmacology. My contributions have been recognized with several awards, including the INSPIRE Award (Andhra Pradesh Government),and First Prize for Patient Information Leaflet (Int

EDUCATION

Pharm D , (

RESEARCH, TEACHING, or OTHER INTERESTS

Endocrinology, Diabetes and Metabolism, Public Health, Environmental and Occupational Health
25

Scopus Publications

81

Scholar Citations

5

Scholar h-index

2

Scholar i10-index

Scopus Publications

  • GLP-1 RAs vs. SGLT2is: Divergent pathways of cardiovascular inflammation control in obesity-associated diabetes
    Ailish Hephzibah Samuel, Abhishek Hanumanpratap Singh Kshatri, Rithwik Nanda Babu, Harsh Shirishkumar Patel, Smera Hari Viswanathan, Mani Shankar Reddy Challa, Swathi N.L.
    Annales D Endocrinologie, 2026
  • Early aggressive treatment with DMARDs vs. step-up therapy in rheumatoid arthritis: a traditional review of joint damage and functional outcomes
    Amruth Akhil Alluri, Aditya Rajesh Pawar, Shrishti Prakash Khetan, Rohan Singhal, Shruti Suresh Suvarna, Mehal Ravindra Adsure, Swathi N.L.
    Journal of Basic and Clinical Physiology and Pharmacology, 2026
    Rheumatoid arthritis (RA) is a chronic autoimmune disease characterized by progressive joint inflammation and structural damage. Two primary treatment strategies – step-up therapy and early aggressive DMARD therapy have been widely debated in clinical practice. The step-up approach begins with NSAIDs or corticosteroids, progressing to DMARDs based on disease severity, whereas early aggressive therapy prioritizes immediate DMARD initiation to prevent irreversible joint damage. This comprehensive review evaluates the effectiveness of these strategies by analyzing randomized controlled trials (RCTs), meta-analyses, and cohort studies assessing treatment outcomes, remission rates, and radiographic progression. A literature search was conducted across PubMed, Scopus, and Web of Science, including studies published between 2010 and 2024. Key clinical trials, including TICORA, COBRA, BeSt, and CAMERA, were critically analyzed to assess the comparative benefits and limitations of both treatment approaches. Evidence suggests that early aggressive therapy is associated with higher remission rates, reduced radiographic progression, and improved long-term physical function, whereas the step-up approach often leads to delayed disease control and cumulative joint damage. However, concerns related to treatment adherence, cost-effectiveness, and safety profiles necessitate further investigation. Future research should focus on biomarker-driven personalized treatment strategies, optimizing drug sequencing, and long-term comparative effectiveness studies to refine RA management.
  • Efficacy of Metabolic and Bariatric Surgery Compared with GLP-1 Receptor Agonist Treatment in Preventing Mortality and Major Adverse Cardiac Events Among Individuals with Obesity and Type 2 Diabetes: A Systematic Review and Meta-analysis
    Joshua Chadwick, Chandru Sivamani, Suchitra Lakshmi, Vishali Baskaran, Swathi N.L., Lavanya Ayyasamy, Ganeshkumar Parasuraman, Bhavani Shankara Bagepally
    Obesity Surgery, 2026
    Obesity and type 2 diabetes mellitus (T2DM) significantly increase cardiovascular morbidity and mortality worldwide. Metabolic and bariatric surgery (MBS) and glucagon-like peptide-1 receptor agonists (GLP-1 RAs) are effective interventions for T2DM and obesity, but comparative evidence on their long-term impact on major adverse cardiovascular events (MACE) and all-cause mortality is lacking. This systematic review and meta-analysis evaluated the efficacy of MBS versus GLP-1 RAs therapy in reducing these outcomes. The review was registered in PROSPERO beforehand and carried out following the PRISMA framework. A comprehensive literature search identified randomized controlled trials (RCTs) and observational studies comparing MBS with GLP-1 RAs regimens in adults with obesity and T2DM. The primary outcomes were all-cause mortality and MACE. We used the Cochrane Risk of Bias 2.0 (ROB 2) tool and Newcastle-Ottawa Scale (NOS) to assess the quality of the study. Meta-analytic techniques were used to synthesize effect estimates. Pooled analysis of eligible studies suggested that MBS offered greater reductions in both MACE and all-cause mortality than GLP-1 RAs therapy. The relative risk reduction for MACE was approximately 52% in favor of MBS. Despite notable heterogeneity, sensitivity analyses confirmed result robustness. The overall certainty of evidence was moderate, reflecting variations in populations, interventions, and study designs. MBS offers significantly greater cardiovascular protection than GLP-1 RAs therapy in individual with obesity and T2DM, reducing MACE and all-cause mortality. GLP-1 RAs remains an important option, particularly for patients contraindicated for surgery or preferring pharmacotherapy. Further long-term comparative and cost effectiveness studies are needed to inform the clinical decisions.
  • The role of the urinary microbiome in diabetes-associated UTIs: Current understanding and future directions
    Meenakshi Reddy Yathindra, Rithvika Badugu, Shaurya Kumar Singh, Sowthrisha Paluri, Hrudai Poudala, Naraginti Leninbabu Swathi
    Journal of Basic and Clinical Physiology and Pharmacology, 2026
    This review explores the interplay between type 2 diabetes mellitus (T2DM) and urinary microbiome dysbiosis, focusing on its role in urinary tract infections (UTIs). Once considered sterile, the urinary tract hosts a diverse microbiota that supports mucosal immunity and pathogen resistance. In T2DM, chronic hyperglycemia and glycosuria disrupt microbial balance, impair immune responses, and increase UTI susceptibility. Glycosuria promotes pathogenic colonization, biofilm formation, and microbial shifts, with studies reporting a threefold rise in Escherichia coli and a 56 % reduction in Lactobacillus spp. in diabetic women with recurrent UTIs. Diabetic urine shows reduced diversity, higher abundance of Klebsiella , Pseudomonas , and Enterococcus , and elevated IL-8. Microbiota-targeted interventions, including probiotics ( Lactobacillus crispatus , Lactobacillus rhamnosus GR-1), prebiotics (astaxanthin), and phytotherapeutics (cranberry), demonstrate potential via lactic acid, hydrogen peroxide production, competitive exclusion, and NF-κB modulation. A 12-month RCT showed significant UTI recurrence reduction with probiotics. Advances in 16 S rRNA sequencing and metagenomics reveal microbial signatures associated with diabetic UTIs, though methodological heterogeneity limits comparability. A review of 1,200 publications (2000–2024) highlights the need for longitudinal studies and precision microbiota therapeutics to translate findings into clinical practice.
  • Berries: bioactive components and their effect on human health
    N.L. Swathi, Ketan Sarvakar, Mandeep Singh Sibian, Vivek Kumar Garg, Shree Rath, Esraa M. AlEdani, Akachukwu Marytheresa Onwuka
    Berries and Nutrition A Holistic Approach to Health, 2026
  • Leveraging AI and ITRS in Drug Discovery for Inflammatory and Cardiovascular Diseases
    N. L. Swathi, Allenki Vineesh, Abhilash Dinesh Sadhankar, Muhammad Muzzamil, Akhil Arun, M. Karpakavalli, Dipanjan Maity, Ancelin Wilfy, J. Anto Musy Bosco, Gaurav Singh Pilkhwal
    Revolutionizing Pharmaceuticals with AI Driven Drug Discovery Design and Development, 2026
    Artificial Intelligence (AI) and Intelligent Translational Research Systems (ITRS) are reshaping drug discovery for inflammatory and cardiovascular diseases by enabling rapid, data-driven identification of novel therapeutic targets and optimization of drug development pipelines. These technologies integrate genomics, proteomics, and clinical data to accelerate translational insights and support personalized treatment strategies. AI models aid in virtual screening, biomarker identification, and adaptive clinical trial designs, reducing time and cost. ITRS further bridge preclinical and clinical domains, enhancing reproducibility and translational relevance. Despite their promise, challenges persist, including algorithmic bias, data privacy concerns, and the need for transparent validation processes. Ethical oversight is essential to ensure fairness and patient safety. Regulatory frameworks must adapt to the evolving digital landscape, emphasizing interoperability, accountability, and real-world applicability.
  • Exosomes and Other Extracellular Vesicles in Regenerative Medicines
    Clinical Potential of Exosomes Diagnostic and Therapeutic Insights, 2026
  • 11β-hydroxysteroid dehydrogenase type 1 (11β-HSD1): A novel therapeutic target in diabetes mellitus
    Receptor Targeted Therapies in Diabetes Mellitus from Pathophysiology to Innovative Treatments, 2025
  • Intermittent fasting versus continuous caloric restriction for glycemic control and weight loss in type 2 diabetes: A traditional review
    Hairya Ajaykumar Lakhani, Deepanwita Biswas, Mahima Kuruvila, Manisha Sai Chava, Kshitij Raj, Joel Thomas Varghese, N.L. Swathi
    Primary Care Diabetes, 2025
  • Incretin-based therapies: Advancements, challenges, and future directions in type 2 diabetes management
    Amruth A. Alluri, Yashaswi Guntupalli, Shruti Suresh Suvarna, Yuliya Prystupa, Shrishti Prakash Khetan, Bharath Vejandla, Naraginti Lenin Babu Swathi
    Journal of Basic and Clinical Physiology and Pharmacology, 2025
    Incretin-based medicines have considerably impacted the treatment of type 2 diabetes mellitus (T2DM), providing considerable advantages in glycemic regulation, weight control, and cardiovascular results. This narrative review examines progress in incretin medicines, encompassing glucagon-like peptide-1 (GLP-1) receptor agonists, dual-receptor, and triple-receptor agonists, while emphasizing their therapeutic advantages, obstacles, and prospective developments. The examined articles were sourced from databases including PubMed and Google Scholar, concentrating on publications predominantly from 2010 to 2024. Selective foundational papers released before this timeline were incorporated to furnish critical historical context about incretin processes and their discovery. Incretin-based medicines, despite their therapeutic efficacy, encounter hurdles including elevated treatment costs, patient compliance difficulties, and variability in response attributable to genetic and physiological variables. Moreover, there are still deficiencies in comprehending the long-term cardiovascular safety and cancer risks linked to these medicines. Emerging dual- and triple-receptor agonists demonstrate potential in overcoming the shortcomings of conventional GLP-1 receptor agonists, providing enhanced metabolic results and broader uses in intricate disease profiles. Future research must concentrate on economic obstacles, streamlined regimens, customized medicine, the integration of artificial intelligence, patient stratification, as well as the safety and efficacy of incretin-based medicines for holistic management of T2DM.
  • The Role of Teledermatology in the COVID-19 Pandemic
    N. L. Swathi, Esraa M. AlEdani
    Updates in Clinical Dermatology, 2025
  • Beyond Borders Global Perspectives on Stem Cell Therapeutics
    N.L. Swathi, Praveen Mallari, Mihir Dabhi, Shweta Shrivastava
    Stem Cell Therapeutics, 2025
  • Application of Artificial Intelligence in Connection with Gut Microbiota to Detect Neurological Disorders
    N.L. Swathi, Kashif Raza Siddique, Habiba Babul, Pranjal Kumar Singh, Dinesh Kumar
    Biotics and the Gutbrain Axis in Neurological Disorders, 2025
  • The Role of Artificial Intelligence in Psoriasis
    N. L. Swathi, Syed Muhammad, Muhammad Muzzamil, Akhil Arun, H. Athul, Esraa M. AlEdani
    Updates in Clinical Dermatology, 2025
  • The Effect of COVID-19 and Its Vaccination on Lichen Planus Exacerbation
    Maleehah Faatimah, N. L. Swathi, Rajeswari Madishetty, Md. Ayesha Sultana, Chittepu Charankumar Reddy, Sangeetha komma, Esraa M. AlEdani
    Updates in Clinical Dermatology, 2025
  • Impact of Covid 19 on Skin Microbiome
    Shaik Firoz, S. Kavitha, G. Swapna, Maleehah Faatimah, Md. Ayesha Sultana, N. L. Swathi, Esraa M. AlEdani
    Updates in Clinical Dermatology, 2025
  • Breast cancer stem cells targeted strategies
    N. L. Swathi, Ishwar Basavan, Evaristus Chinonso Odoh, Shadrach Chinecherem Eze, Jawahar Chowdary Sushma Swaraj, Nandini Sharma
    Spatially Variable Genes in Cancer Development Progression and Treatment Response, 2024
  • Mindfulness training for cardiovascular health in type 2 diabetes: A critical review
    Arnav Gandhi, Rhenita Rajkumar, Sanjay Nehru Dakka, Jeba Sania, Fatima Khurram, Jorge Cabrera, Swathi N․L․
    Current Problems in Cardiology, 2024
  • Immunological insights into nutritional deficiency disorders
    Azraida Hajar, N. L. Swathi, Awais Ali
    Causes and Management of Nutritional Deficiency Disorders, 2024
  • Advanced technologies in clinical research and drug development
    N. L. Swathi, Achukutla Kumar
    Ethical Frontier of AI and Data Analysis, 2024
  • Precision medicine and epigenetics: Personalized diabetes care
    N. L. Swathi, Ishwar Basavan, Muhammad Muzzamil, Aparna Venkatesan, Gorthy Shanmukha Rama, Akhil Arun
    Biomedical Research Developments for Improved Healthcare, 2024
  • Precision medicine: Insights from case studies and cutting-edge technologies
    N. L. Swathi, Madhurita Chakrabarti, Muhammad Muzzamil, Hiba Hamdar, Ahmad Jaber, Amarelle Chamoun, Fatima Al Amin, Pooja Rathod
    Medical Robotics and AI Assisted Diagnostics for A High Tech Healthcare Industry, 2024
  • Healthcare Information Systems Management
    N. L. Swathi, S. Kavitha, M. Karpakavalli
    Improving Healthcare Quality and Patient Engagement Management and Technology Insights, 2024
  • Medicinal and Nutritional Importance of Punica granatum in Human Health
    N. L. Swathi, Vanshika Vishnoi, K. Swathi Priya, Akachukwu Marytheresa Onwuka
    Medicinal Plants and their Bioactive Compounds in Human Health Volume 1, 2024
  • Artificial intelligence and its integration with regenerative medicine approach
    Tungki Pratama Umar, Dessy Agustini, Abdelrahman M. Makram, Muhammad Muzzamil, Bella Stevanny, Randa Elsheikh, N. L. Swathi, Tulika Garg, Aulia Ananditia Putri, Nityanand Jain
    Integrating Digital Health Strategies for Effective Administration, 2023

RECENT SCHOLAR PUBLICATIONS

  • Early aggressive treatment with DMARDs vs. step-up therapy in rheumatoid arthritis: a traditional review of joint damage and functional outcomes
    A Akhil Alluri, A Rajesh Pawar, S Prakash Khetan, R Singhal, ...
    Journal of Basic and Clinical Physiology and Pharmacology 37 (2), 71-93 , 2026
    2026
  • GLP-1 RAs vs. SGLT2is: Divergent Pathways of Cardiovascular Inflammation Control in Obesity-Associated Diabetes
    AH Samuel, AHS Kshatri, RN Babu, HS Patel, SH Viswanathan, ...
    Annales d'Endocrinologie, 102494 , 2026
    2026
    Citations: 1
  • Efficacy of Metabolic and Bariatric Surgery Compared with GLP-1 Receptor Agonist Treatment in Preventing Mortality and Major Adverse Cardiac Events Among Individuals with …
    J Chadwick, C Sivamani, S Lakshmi, V Baskaran, S NL, L Ayyasamy, ...
    Obesity Surgery, 1-12 , 2026
    2026
  • The role of the urinary microbiome in diabetes-associated UTIs: current understanding and future directions
    MR Yathindra, R Badugu, SK Singh, S Paluri, H Poudala, NL Swathi
    Journal of Basic and Clinical Physiology and Pharmacology 37 (1), 9-24 , 2026
    2026
  • Exosomes and Other Extracellular Vesicles in Regenerative Medicines
    SS Vasudevan, TY Kandrikar, NL Swathi, MB Shabbir, N Vora, A Shabbir, ...
    Clinical Potential of Exosomes, 551-602 , 2026
    2026
  • Berries: bioactive components and their effect on human health
    NL Swathi, K Sarvakar, MS Sibian, VK Garg, S Rath, EM AlEdani, ...
    Berries and Nutrition, 139-160 , 2026
    2026
    Citations: 1
  • Leveraging AI and ITRS in Drug Discovery for Inflammatory and Cardiovascular Diseases
    NL Swathi, A Vineesh, AD Sadhankar, M Muzzamil, A Arun, ...
    Revolutionizing Pharmaceuticals With AI-Driven Drug Discovery, Design, and … , 2026
    2026
  • Early aggressive treatment with DMARDs vs. step-up therapy in rheumatoid arthritis: a traditional review of joint damage and functional outcomes.
    A Alluri, R Pawar, R Adsure
    Journal of Basic and Clinical Physiology and Pharmacology , 2025
    2025
  • Terpenoids modulation of the IFI16-AIM2 interaction for enhanced immune response in lung squamous cell carcinoma and AIM2-dysregulated diseases
    A Ali, A Alamri, W Ullah, T Waseem, SL Ali, T Al Arian, NL Swathi
    In Silico Pharmacology 13 (3), 1-29 , 2025
    2025
    Citations: 5
  • Application of Artificial Intelligence in Connection with Gut Microbiota to Detect Neurological Disorders
    NL Swathi, KR Siddique, H Babul, PK Singh, D Kumar
    Biotics and the Gut–Brain Axis in Neurological Disorders, 334-349 , 2025
    2025
  • Parkinson’s Disease and Gut Microbiota
    S NL, TP Umar, WI Abo-Elenien, S Bhagat, AS Al Sakini, SN Rai
    Microbiota Profiling for Precision Medicine: Biomarker-Targeted Drug … , 2025
    2025
  • Parkinson's Disease and Gut Microbiota
    NL Swathi, TP Umar, WI Abo-Elenien, S Bhagat, AS Al Sakini, SN Rai
    Microbiota Profiling for Precision Medicine: Biomarker-Targeted Drug … , 2025
    2025
  • MON-804 Cracks in the Foundation: Temporal and Geographic Trends in Bone Disorder Mortality in the US
    MZ Jan Kakakhel, S Cheema, R Haider, R Noor, S NL, SM Irshad, A Ullah, ...
    Journal of the Endocrine Society 9 (Supplement_1), bvaf149. 546 , 2025
    2025
  • SUN-608 Diabetes and Chronic Kidney Disease: A Two-Decade Analysis of Mortality Trends and Demographic Disparities
    MZ Jan Kakakhel, S Cheema, R Haider, F Saleem, A Ullah, M Shah, ...
    Journal of the Endocrine Society 9 (Supplement_1), bvaf149. 1257 , 2025
    2025
    Citations: 2
  • The Role of Artificial Intelligence in Psoriasis
    NL Swathi, S Muhammad, M Muzzamil, A Arun, H Athul, EM AlEdani
    Applications of Artificial Intelligence in Common Dermatological Diseases, 19-38 , 2025
    2025
  • Beyond Borders: Global Perspectives on Stem Cell Therapeutics
    NL Swathi, P Mallari, M Dabhi, S Shrivastava
    Stem Cell Therapeutics, 705-738 , 2025
    2025
  • The Effect of COVID-19 and Its Vaccination on Lichen Planus Exacerbation
    M Faatimah, NL Swathi, R Madishetty, M Ayesha Sultana, CC Reddy, ...
    COVID-19 Vaccination and Dermatological Diseases, 33-44 , 2025
    2025
  • Impact of Covid 19 on Skin Microbiome
    S Firoz, S Kavitha, G Swapna, M Faatimah, M Ayesha Sultana, NL Swathi, ...
    COVID-19 Vaccination and Dermatological Diseases, 97-109 , 2025
    2025
  • The Role of Teledermatology in the COVID-19 Pandemic
    NL Swathi, EM AlEdani
    COVID-19 Vaccination and Dermatological Diseases, 89-96 , 2025
    2025
  • COVID-19 Vaccination and Dermatological Diseases
    EM AlEdani, H Maibach
    Springer Nature Switzerland , 2025
    2025

MOST CITED SCHOLAR PUBLICATIONS

  • Currently trending and futuristic biological modalities in the management of different types of diabetes: A comprehensive review
    A ALi, U Manzoor, SL Ali, MD Marsool, PK Parida, AD Marsool, NL Swathi
    J Popul Ther Clin Pharmacol 30 (18), 2948-70 , 2023
    2023
    Citations: 16
  • Incretin-based therapies: advancements, challenges, and future directions in type 2 diabetes management
    AA Alluri, Y Guntupalli, SS Suvarna, Y Prystupa, SP Khetan, B Vejandla, ...
    Journal of Basic and Clinical Physiology and Pharmacology 36 (2-3), 95-111 , 2025
    2025
    Citations: 11
  • Intermittent fasting versus continuous caloric restriction for glycemic control and weight loss in type 2 diabetes: A traditional review
    HA Lakhani, D Biswas, M Kuruvila, MS Chava, K Raj, JT Varghese, ...
    Primary Care Diabetes 19 (3), 203-213 , 2025
    2025
    Citations: 8
  • Epigenetic mechanisms in the transfer of metabolic disorders: a comprehensive review
    NL Swathi, Z Shakhatreh, A Tahir, J Singh, S Sulaiman, H Athul, ...
    Cureus 17 (3) , 2025
    2025
    Citations: 7
  • Causes and Management of Nutritional Deficiency Disorders
    A Nayak, S Misra
    IGI Global , 2024
    2024
    Citations: 6
  • Terpenoids modulation of the IFI16-AIM2 interaction for enhanced immune response in lung squamous cell carcinoma and AIM2-dysregulated diseases
    A Ali, A Alamri, W Ullah, T Waseem, SL Ali, T Al Arian, NL Swathi
    In Silico Pharmacology 13 (3), 1-29 , 2025
    2025
    Citations: 5
  • Immunological insights into nutritional deficiency disorders
    A Hajar, NL Swathi, A Ali
    Causes and Management of Nutritional Deficiency Disorders, 61-84 , 2024
    2024
    Citations: 5
  • Mindfulness training for cardiovascular health in type 2 diabetes: A critical review
    A Gandhi, R Rajkumar, SN Dakka, J Sania, F Khurram, J Cabrera
    Current Problems in Cardiology 49 (12), 102833 , 2024
    2024
    Citations: 4
  • Artificial Intelligence and Its Integration with Regenerative Medicine Approach
    Integrating Digital Health Strategies for Effective Administration 3, 32 -57 , 2023
    2023
    Citations: 4
  • Healthcare Information Systems Management
    NL Swathi, S Kavitha, M Karpakavalli
    Improving Healthcare Quality and Patient Engagement: Management and … , 2025
    2025
    Citations: 3
  • SUN-608 Diabetes and Chronic Kidney Disease: A Two-Decade Analysis of Mortality Trends and Demographic Disparities
    MZ Jan Kakakhel, S Cheema, R Haider, F Saleem, A Ullah, M Shah, ...
    Journal of the Endocrine Society 9 (Supplement_1), bvaf149. 1257 , 2025
    2025
    Citations: 2
  • Precision medicine and epigenetics: personalized diabetes care
    NL Swathi, I Basavan, M Muzzamil, A Venkatesan, GS Rama, A Arun
    Biomedical Research Developments for Improved Healthcare, 288-309 , 2024
    2024
    Citations: 2
  • Advanced Technologies in Clinical Research and Drug Development
    NL Swathi, A Kumar
    The Ethical Frontier of AI and Data Analysis, 1-17 , 2024
    2024
    Citations: 2
  • GLP-1 RAs vs. SGLT2is: Divergent Pathways of Cardiovascular Inflammation Control in Obesity-Associated Diabetes
    AH Samuel, AHS Kshatri, RN Babu, HS Patel, SH Viswanathan, ...
    Annales d'Endocrinologie, 102494 , 2026
    2026
    Citations: 1
  • Berries: bioactive components and their effect on human health
    NL Swathi, K Sarvakar, MS Sibian, VK Garg, S Rath, EM AlEdani, ...
    Berries and Nutrition, 139-160 , 2026
    2026
    Citations: 1
  • Evaluating the Impact of Individualized Interventions on Diabetes Distress and Glycemic Outcomes: A Shift From Glycated Hemoglobin (HbA1c) to Random Blood Sugar (RBS) in a …
    NL Swathi, M Devadarshini, AP Mohammed, D Jothieswari, M Umar, ...
    Cureus 17 (3) , 2025
    2025
    Citations: 1
  • Breast Cancer Stem Cells Targeted Strategies
    NL Swathi, I Basavan, EC Odoh, SC Eze, JCS Swaraj, N Sharma
    Spatially Variable Genes in Cancer: Development, Progression, and Treatment … , 2025
    2025
    Citations: 1
  • Medicinal and Nutritional Importance of Punica granatum in Human Health
    NL Swathi, V Vishnoi, KS Priya, AM Onwuka
    Medicinal Plants and their Bioactive Compounds in Human Health: Volume 1 … , 2024
    2024
    Citations: 1
  • Fetal and Neonatal Outcomes in Booked vs. UnBooked Deliveries: A Systematic Review and Meta-analysis of the Global Literature
    J Mansoor, U Hafeez, NU Khan, A Ali, R Zubair, NL Swathi, A Nadeem, ...
    2024
    Citations: 1
  • Early aggressive treatment with DMARDs vs. step-up therapy in rheumatoid arthritis: a traditional review of joint damage and functional outcomes
    A Akhil Alluri, A Rajesh Pawar, S Prakash Khetan, R Singhal, ...
    Journal of Basic and Clinical Physiology and Pharmacology 37 (2), 71-93 , 2026
    2026